Lyon Uveitis Study (LYS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03877575|
Recruitment Status : Recruiting
First Posted : March 15, 2019
Last Update Posted : March 15, 2019
Uveitis or inflammation of the uveal tract results from a heterogeneous collection of disorders of varying etiologies and pathogenic mechanisms. Uveitis is relatively frequent in industrial countries with an estimation of 115 cases for 100 000 persons and is associated with a blindness risk of 10%. Causes of uveitis can be related to different etiologies (infectious, inflammatory or general inflammatory diseases). Therapeutic care is based on ophthalmologic and systemic diagnosis and treatment strategy depends on the severity of inflammation.
The main objective of the Lyon uveitis study is to analyze the uveitis ophthalmologic etiology and diagnostic and therapeutic care of the patients. This study is proposed to all patients diagnosed for uveitis and referred to the Department of Internal Medicine of the Croix Rousse hospital, Lyon, france for etiologic diagnosis or treatment.
Analysis of i) patients' characteristics, ii) the relevance of complementary exams to determine the uveitis etiology, iii) treatment used.
This study will allow a better characterization of the disease on diagnosis practices and therapeutic care.
|Condition or disease||Intervention/treatment|
|Uveitis||Other: No specific intervention. Collection of clinical data|
|Study Type :||Observational|
|Estimated Enrollment :||750 participants|
|Official Title:||Lyon Uveitis Study|
|Actual Study Start Date :||January 1, 2016|
|Estimated Primary Completion Date :||January 1, 2023|
|Estimated Study Completion Date :||January 1, 2023|
- Clinical evolution (persistence or resolution) evaluated by gradation of SEN [ Time Frame: At one year after diagnosis ]Persistence of disease is characterized by persistence of intraocular inflammation evaluated by gradation of SEN. (reference: A Standardization Grading System for Scleritis . Ophthalmology 2011 Apr;118(4):768-71). SEN score ranges from 0 to 5 (resolution = score 0 and persistence = score >0)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03877575
|Contact: Pascal Sève, MD, PhD||+33-4 26 73 26 firstname.lastname@example.org|
|Department of Internal Medicine, Croix-Rousse Hospital, Hospices Civils de Lyon||Recruiting|
|Lyon, France, 69004|
|Contact: Pascal Sève, MD, PhD +33-4 26 73 26 27 email@example.com|